Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MM120

Phase 3Small molecule

DDefinium Therapeutics US, Inc.

MM120 is one of 101 small molecule programs targeting Anxiety. It is currently in Phase 3.

3

Indications

5

Total Trials

3

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

Major Depressive DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

AnxietyPhase 2

Active, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Ketalar

Boehringer Ingelheim

ALKS 37

AAlkermes, Inc.

Brenipatide

Rapastinel

DVS-233

TC-5214

NBI-1065845

Neurocrine Biosciences

Vortioxetine MR

MM120

DDefinium Therapeutics US, Inc.

NMRA-335140

NNeumora Therapeutics, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06741228

Q1 2027

Phase 3Active, not recruiting

Major Depressive Disorder

NCT06941844

Q2 2027

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06809595

Clinical

Trials by Indication[1]

Generalized Anxiety Disorder2 trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06741228·214 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06809595·245 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

Completed·DDefinium Therapeutics US, Inc.·Phase 2·NCT05200936·53 enrolled

Anxiety1 trial

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Completed·DDefinium Therapeutics US, Inc.·Phase 2·NCT05407064·198 enrolled

Major Depressive Disorder1 trial

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06941844·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MM120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MM120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MM120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Definium Therapeutics US, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDefinium Therapeutics US, Inc.

Related News